US equities |
MU $1,097.39 ▲+0.00% NVDA $230.86 ▲+0.00% SNDK $1,787.69 ▲+0.00% MSTR $160.50 ▲+0.00% NKE $35.15 ▲+0.00% INTC $120.00 ▲+0.00% AMD $615.73 ▲+0.00% AVGO $343.64 ▲+0.00%
FinancialContent

GlucoTrack, Inc. - Common Stock (NQ:GCTK)

1.410 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about GlucoTrack, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Lōkahi Therapeutics™ Expands University of Georgia Collaboration Through First International ai² Pipeline™ Project with Universität Paderborn
From Lōkahi Therapeutics
Via Business Wire
News headline image
Lōkahi Therapeutics™ Announces Qare™, the First Real-Time Comparative Health Platform for GLP-1 Medications, with Public Availability Beginning October 14
From Lōkahi Therapeutics
Via Business Wire
News headline image
Lōkahi Therapeutics™ Expands ai2 Pipeline™ Program Through Collaboration with Pepperdine E2B™
From Lōkahi Therapeutics
Via Business Wire
News headline image
Emerging Growth DRK GLND APUS GCTK Stocks in the News
Via AB Newswire
Topics Artificial Intelligence
News headline image
DarkHorse (NASDAQ: DRK) Strategic Partners Power Up AI Data Center Expansion Across TVA Region
Via AB Newswire
Topics Artificial Intelligence
News headline image
Glucotrack, Inc. Announces Pricing of $3 Million Public Offering
From Glucotrack, Inc.
Via Business Wire
News headline image
Lōkahi Therapeutics™ Advances its Proprietary ai² PIPELINE (formerly ai² Futures Lab) Process from Internal Asset Engine to Revenue-Generating Platform
From Lōkahi Therapeutics
Via Business Wire
News headline image
Lōkahi Therapeutics™ and Glucotrack CEO Erik Emerson Provides Strategic Update on LT-100, ai² Platform Growth and Clinical Development Priorities
From Lōkahi Therapeutics
Via Business Wire
News headline image
Lōkahi Therapeutics™ Continues ai² Pipeline™ Division Collaboration with The University of Alabama to Advance Asset Evaluation and Biopharma Talent
From Lōkahi Therapeutics
Via Business Wire
News headline image
Glucotrack Announces $11.5 Million Financing
From Glucotrack, Inc.
Via Business Wire
News headline image
Lōkahi Therapeutics™ Expands ai² Into Three Opportunity-Creating Business Divisions
From Lōkahi Therapeutics Inc.
Via Business Wire
News headline image
Lōkahi Therapeutics™ Expands ai² Futures Lab™ Asset Origination Network Through Collaboration with San Diego State University Fowler College of Business
From Lōkahi Therapeutics
Via Business Wire
News headline image
Glucotrack, Inc. Announces Reverse Stock Split
From Glucotrack, Inc.
Via Business Wire
News headline image
Lōkahi Therapeutics™ Initiates Clinical Trial Manufacturing for LT-100
From Lōkahi Therapeutics Inc.
Via Business Wire
News headline image
Lōkahi Therapeutics™ Expands ai² Futures Lab™ Asset Origination Network Through Continued Collaboration with the University of Georgia
From Lōkahi Therapeutics
Via Business Wire
News headline image
Glucotrack Achieves Key Compliance Milestone and Advances Strategic Transformation
From Glucotrack, Inc.
Via Business Wire
News headline image
Glucotrack Announces $5.5 Million Financing
From Glucotrack
Via Business Wire
News headline image
CORRECTING and REPLACING Lōkahi Therapeutics™ ai² Futures Lab™ Changes How Biopharma Builds a Pipeline
From Lōkahi Therapeutics Inc.
Via Business Wire
News headline image
Lōkahi Therapeutics™ Advances LT-100 Development Strategy Toward Single-Injection Administration
From Lōkahi Therapeutics Inc.
Via Business Wire
News headline image
Glucotrack, Inc. and Lōkahi Therapeutics™ Announce Strategic Financing Support from E.F. Hutton & Co. in Connection with Their Recently Completed Business Combination and Future Capital Markets Initiatives
From Glucotrack, Inc.; Lōkahi Therapeutics
Via GlobeNewswire
News headline image
UPDATE – Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform
Transaction positions the combined company to execute a capital-efficient, repeatable strategy leveraging public market access and Lōkahi Therapeutics ai²-driven asset sourcing, development, and... 
From Glucotrack, Inc.; Lōkahi Therapeutics
Via GlobeNewswire
News headline image
Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform
Transaction positions the combined company to execute a capital-efficient, repeatable strategy leveraging public market access and Lōkahi Therapeutics ai²-driven asset sourcing, development, and... 
From Glucotrack, Inc.; Lōkahi Therapeutics
Via GlobeNewswire
News headline image
Glucotrack Announces USPTO Notice of Allowance for Patent Application Covering Its Implantable CBGM Platform
From Glucotrack, Inc.
Via GlobeNewswire
News headline image
Glucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association’s 2026 Scientific Sessions
From Glucotrack, Inc.
Via GlobeNewswire
News headline image
Glucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring Technology
Submission supports advancement of a long‑term, fully implantable, blood‑based continuous glucose monitoring platform 
From Glucotrack, Inc.
Via GlobeNewswire
News headline image
Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology
In-Vivo Ovine Study Demonstrates Sustained Performance Of Company’s Continuous Blood Glucose Monitoring (CBGM) Technology Over 240 Days, Reinforces Path to Key IDE Submission 
From Glucotrack, Inc.
Via GlobeNewswire
News headline image
Glucotrack Announces Publication of Peer-Reviewed Study Supporting Long-Life Sensor Design for Implantable Continuous Blood Glucose Monitoring Technology
Year-long in-vitro characterization of glucose oxidase stability supports the feasibility of long-life implantable continuous glucose monitors, independent third party review of the longevity and... 
From Glucotrack, Inc.
Via GlobeNewswire
News headline image
Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones
Experience From Brazilian and Australian Clinical Trials Positions the Company to Submit Investigational Device Exemption (IDE) to FDA for Novel CBGM Technology in Q2 2026 
From Glucotrack, Inc.
Via GlobeNewswire
News headline image
Glucotrack to Present at LSI USA ’26 Medtech Innovation Summit
From Glucotrack, Inc.
Via GlobeNewswire
News headline image
Glucotrack Announces USPTO Approval for Issuance of Patents for Proprietary CBGM Platform
From Glucotrack, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >